It is likely that more granular subphenotypes exist beyond the HFrEF/HFmrEF/HFpEF trichotomy
Thorens, Hodson)
In a Phase I single ascending dose study in healthy participants, LY3437943 showed a similar safety and tolerability profile to that of other incretins and a reduction in body weight up to day 43 after a single dose [97]
The complaint alleges that, in reality, defendants understated the ongoing impact of the personalization exception to the compounded GLP-1 exclusion, overstated the likelihood that patients would switch to Novo's branded alternatives, and overstated the GLP-1 market's expansion or Novo's ability to penetrate it to achieve continued growth
Csukly G, Sirly E, Fodor Z, Horvth A, Salacz P, Hidasi Z, et al
(2023) Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action Muller, Neerav et al